Medication & Safety
How Much Does Ozempic Cost? A Country-by-Country Guide
Ozempic costs $800–$1000 per month in the US without insurance. Costs vary widely globally. Here is the complete breakdo...
Ozempic and phentermine both suppress appetite — but through completely different mechanisms, with very different safety profiles, and appropriate for different patient situations. Understanding both helps clarify why GLP-1 agonists have largely replaced older appetite suppressants as the preferred pharmacological approach to obesity.
What Phentermine Is
Phentermine is a sympathomimetic amine — it stimulates the release of adrenaline and noradrenaline (epinephrine and norepinephrine), which suppress appetite through the sympathetic nervous system. It is the oldest approved weight loss medication still in common use, first approved by the FDA in 1959.
It works quickly and produces significant appetite suppression within days. It is available as a generic at low cost.
What Ozempic Is
Ozempic (semaglutide) is a GLP-1 receptor agonist that suppresses appetite through the hypothalamus and reduces gastric emptying, producing sustained satiety without stimulant effects.
Weight Loss Comparison
Phentermine: Short-term trials (12 weeks) show 3 to 6 kg average weight loss. It is approved only for short-term use (3 months) in the US because long-term safety data does not support extended treatment and tolerance (reduced effect) develops with continued use.
Ozempic (semaglutide for diabetes, 1 mg): 4 to 6 kg over 52 weeks. Wegovy (semaglutide for obesity, 2.4 mg): 14.9% of body weight over 68 weeks — approximately 13 to 17 kg for most patients.
For sustained weight loss beyond three months, semaglutide significantly outperforms phentermine.
Why Phentermine Cannot Match Long-Term Results
Phentermine produces tolerance: the body adapts to sympathomimetic stimulation and the appetite-suppressing effect diminishes over weeks. This is why it is only approved for short-term use. It does not address the underlying hormonal drivers of hunger — it overrides them temporarily with a stimulant signal that the body learns to compensate for.
Semaglutide works through the body's own satiety hormone system (GLP-1), producing sustained effects that do not diminish through tolerance at therapeutic doses. The appetite suppression continues for as long as treatment is maintained.
Side Effect Profile
Phentermine: Increases heart rate and blood pressure. Causes insomnia, dry mouth, irritability, and anxiety in many users. Is contraindicated in heart disease, hyperthyroidism, glaucoma, and pregnancy. Not appropriate for patients with anxiety disorders, cardiac history, or hypertension.
Ozempic: GI side effects (nausea, constipation) concentrated in the first weeks. No cardiovascular stimulant effects. Actually shows cardiovascular benefit in SELECT trial. Contraindicated in MTC/MEN2 history.
For patients with cardiovascular disease or hypertension — common in people with obesity — phentermine's stimulant effects are often a reason it cannot be used.
Phentermine/Topiramate Combination
Qsymia (phentermine/topiramate extended-release) is an approved weight loss medication combining low-dose phentermine with topiramate (an anticonvulsant with weight loss effects). Average weight loss at maximum dose is approximately 10% of body weight over 12 months — better than phentermine alone but still less than semaglutide 2.4 mg.
Which Is Appropriate When
Phentermine may be appropriate for short-term kickstart weight loss in people without cardiovascular contraindications, when immediate appetite suppression is the priority and cost is a significant barrier to GLP-1 agonists.
Semaglutide (or GLP-1 pathway support) is appropriate for sustained, long-term weight management, particularly in patients with cardiovascular risk, diabetes, or who need more than a short-term intervention.
The Pakistani Access Context
Phentermine has complex regulatory status in many countries (Schedule IV in the US; not universally approved elsewhere). For Pakistani patients seeking weight loss support, METASLIM provides GLP-1 pathway activation through sublingual delivery with physician oversight — addressing the same appetite signalling system as semaglutide without the stimulant cardiovascular risks of phentermine and without the access barriers of prescription-only pharmaceutical GLP-1 drugs.